STOCK TITAN
  1. Home
  2. News
  3. SILO

SILO Pharma Inc - SILO STOCK NEWS

Welcome to our dedicated news page for SILO Pharma (Ticker: SILO), a resource for investors and traders seeking the latest updates and insights on SILO Pharma.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect SILO Pharma's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of SILO Pharma's position in the market.

News
Silo Pharma Announces Positive Results for Intranasal PTSD Treatment
Rhea-AI Summary
Silo Pharma, Inc. (Nasdaq: SILO) announces positive data for intranasal PTSD treatment SPC-15, showing rapid absorption and consistent exposure. The PK study results indicate effective drug administration. CEO Eric Weisblum believes the results will translate well to humans, paving the way for further clinical studies and FDA application in 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.55%
Tags
none
-
News
Silo Pharma set to Acquire Exclusive Licensing for Promising Alzheimer’s Disease Therapeutic
Rhea-AI Summary
Silo Pharma, Inc. announces the licensing of Alzheimer's disease therapeutic SPC-14 from Columbia University, showing cognitive and stress reduction benefits in preclinical models. The Company aims to develop, manufacture, and commercialize SPC-14 globally, expecting to finalize the exclusive license agreement in the first half of 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.87%
Tags
acquisition
-
News
Silo Pharma Exercises Option for Exclusive License Agreement for First-in-Class PTSD and Stress-Induced Anxiety Therapeutic
Rhea-AI Summary
Silo Pharma, Inc. has secured an exclusive license for the development, manufacturing, and commercialization of SPC-15, a prophylactic treatment for stress-induced affective disorders, including anxiety and PTSD. The company expects to finalize the license agreement in the first half of 2024 after successful pre-clinical development and FDA pre-IND application. SPC-15 offers a unique approach to treating PTSD by enhancing stress resilience in high-risk populations, differentiating it from existing treatments.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.43%
Tags
none
News
Silo Pharma Files Patent for Groundbreaking Ketamine Implant Therapeutic to Target Fibromyalgia and Chronic Pain
Rhea-AI Summary
Silo Pharma, Inc. files a patent application for SP-26 implantable drug delivery system for time-release and dosage control of ketamine, targeting fibromyalgia. The company believes it could revolutionize chronic pain management.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.72%
Tags
none
-
News
Silo Pharma Completes Successful Dose-Ranging Study of SPC-15 Intranasal Therapeutic for PTSD
Rhea-AI Summary
Silo Pharma, Inc. announces positive results from a non-GLP small animal dose-ranging study of SPC-15, a potential intranasal treatment for anxiety and PTSD. The study identified the maximum tolerated dose and determined a once-per-day dosing regimen for human clinical trials. The data suggests rapid absorption and good exposure over 24 hours, paving the way for IND submission to the FDA by the end of the second quarter 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.52%
Tags
none
-
News
Silo Pharma’s SP-26 Ketamine Implant Demonstrates Successful Drug Delivery
Rhea-AI Summary
Silo Pharma, Inc. provides a positive update on SP-26, a novel time-released, dose-controlled formulation of ketamine targeting fibromyalgia. Pre-clinical research is ongoing to determine drug release and stability, showing successful loading and encapsulation of ketamine in polymer implants. Structural integrity of the implants is maintained, indicating potential for sustained drug delivery for chronic pain conditions.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.62%
Tags
none
News
Silo Pharma Announces Positive Results in Alzheimer’s Disease Study
Rhea-AI Summary
Silo Pharma, Inc. (Nasdaq: SILO) announced positive results from a preclinical study showing the effectiveness of its Alzheimer’s disease therapeutic SPC-14 in small animals. The study, conducted in collaboration with Columbia University, demonstrated that SPC-14 was effective in attenuating LH stress, learned helplessness, perseverative behavior, and anxiety in mice. The company is optimistic about the potential of SPC-14 to provide relief to patients and families suffering from Alzheimer’s disease, and plans to update shareholders on the next steps for advancing the therapeutic to a clinical study.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.71%
Tags
none
-
News
Silo Pharma Successfully Completes First Phase of Dose-Ranging Study of SPC-15 an Intranasal Treatment for PTSD
Rhea-AI Summary
Silo Pharma, Inc. (Nasdaq: SILO) is a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research. The company provided an update on its dose-ranging study of SPC-15, a targeted prophylactic treatment for post-traumatic stress disorder (PTSD), with the final validation report expected in the first quarter of 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.2%
Tags
none
-
News
Silo Pharma and Partner Receive Regulatory Approval to Begin Development of Ketamine Implant for Fibromyalgia
Rhea-AI Summary
Silo Pharma, Inc. (Nasdaq: SILO) is developing a potential at-home pain relief treatment for fibromyalgia and other chronic pain conditions. The company's dosage and time-release ketamine-loaded implant, designated as SP-26, is advancing through analytical testing and small batch pre-clinical proof of concept extrusion trials in collaboration with Sever Pharma Solutions. The implant formulation will be studied utilizing the subcutaneous injection method, with Silo intending to pursue the FDA’s streamlined 505(b)(2) pathway for approval of SP-26.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-11%
Tags
none
News
Silo Pharma Enters into Exclusive License Agreement with Medspray Pharma BV for Intranasal Technology used in SPC-15 Treatment for PTSD
Rhea-AI Summary
Silo Pharma, Inc. (Nasdaq: SILO) has announced an exclusive license agreement with Medspray Pharma BV for its patented soft mist nasal spray technology to be used with Silo's intranasal therapeutic drug SPC-15. The technology will cover multiple indications including anxiety disorders, Alzheimer’s disease, and anorexia, providing a valuable asset for Silo's research and development of novel therapeutics.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
12.95%
Tags
none
Stock SILO logo
SILO Pharma Inc

Nasdaq:SILO

SILO Rankings

N/A Ranked by Market Cap
N/A Ranked by Stock Gains
N/A Ranked by Dividends

SILO Stock Data

5.60M
2.54M
6.35%
5.65%
2.16%
Securities and Commodity Exchanges
Finance and Insurance
Link
United States
Englewood Cliffs

About SILO

silo pharma inc. (nasdaq: silo), a developmental stage biopharmaceutical company, is focused on merging traditional therapeutics with psychedelic research for people suffering from indications such as post-traumatic stress disorder, fibromyalgia, alzheimer’s disease, parkinson’s disease, and other rare neurological disorders. silo’s mission is to identify assets to license and fund research that the company believes will be transformative to the wellbeing of patients and the health care industry. silo is committed to developing innovative solutions to address a variety of underserved conditions. combining silo’s resources with world-class medical research partners, the company looks to make significant advances in the medical and psychedelic space. silo works to identify and partner with leading medical universities, providing the needed financial resources to develop safe therapeutic treatments while moving cutting-edge research through the clinical stage and into commercialization.